The acute destructive pneumonias (ADP) occupy up to 80% of the total number of pneumonias. They require constant improvement of treatment strategy. Nowadays the use of surfactants is a part of most treatment protocols. The aim was to study the features of the solid phase bronchoalveolar lavage in children with the ADPs in the dynamics of complex treatment with exogenous surfactant. Material and methods: We examined 39 patients of contaminated surgery. We identified 2 groups of patients. The patients of first group (n=27) had pulmonary pleural form of ADP, the second group (n=12) had pulmonary form of ADP. All patients got classical treatment and the earlier draining of pleural cavity. We used as an antiseptic reamberin 1.5% by 10 ml/kg and endobronchially injected exogenous surfactant Bl in dose12 mg/kg body weight a day, 6 mg/kg every 12 hours. All the children were made a bronchoscopy to obtain BAL to study the crystallization properties. The solid phase of BAL was studied by method of cuneal dehydration. Results: All facies before treatment were divided into two groups according to classification of facies of biological fluids. Only the facies of the second and the third types were detected there. It was revealed that the sizes of the zones of the facies were different in the comparison groups before treatment and after. And the level of crystalline structures and amorphous aggregates were different in the groups with different degrees of inflammation. Conclusion: So, we can assume that the change in surfactant system is characterized by changes in the morphological structure of solids phases of BAL. And the morphological structure of BAL depends on the chemical composition of BAL., Yuliya Modna, Tatiana Tananakina, Elina Dyka, Ievgen Mozhaiev, Pavlo Borodin, and Literatura
Cíl studie: Tato práce sleduje pacienty s akutním koronárním syndromem a k diagnostice akutního infarktu myokardu (AIM) využívá zcela nové technologie proteinových biočipů. Snahou je nejenom ohodnotit tuto novou možnost laboratorní diagnostiky AIM, ale také srovnání méně známých kardiomarkerů se standardními markery a posouzení jejich vztahu ke klinickým parametrům. Materiál a metody: Do studie bylo celkem zařazeno 44 pacientů s diagnózou AIM a krevní odběry byly prováděny v den přijetí, za 24 hodin a poté čtvrtý nebo pátý den hospitalizace. Z kardiomarkerů byl testován panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP a GPBB) na biočipovém analyzátoru The Evidence InvestigatorTM od firmy Randox (Randox Laboratories Ltd., Velká Británie). Výsledky: Naše práce potvrdila těsný vztah FABP a GPBB k AIM a na základě jejich dynamiky je můžeme považovat za časné kardiomarkery. Zároveň jsme zjistili, že FABP má, stejně jako standardní marker CKMB nebo TnI, také prognostický význam - vyšší hodnoty jsou spojené se systolickou dysfunkcí. Také jsme poukázali na možnost využití biočipového analyzátoru při diagnostice AIM, kdy za poměrně krátký časový úsek získáme výsledky několika analytů najednou, které nám tak podají širší informace o probíhajícím AIM. Závěr: Metoda proteinových biočipů představuje v diagnostice AIM nový efektivní přístup, který ale jistě ke svému rozšíření vyžaduje řadu dalších studií., Objective: This study observes patients with acute coronary syndromes. To the diagnosis of acute myocardial infarction (AIM) we use the new proteins biochip technologies. The aim of this study is to evaluate the new strategy of laboratory diagnostic method and to confront the less known’s cardio markers with the standard markers and with the clinical parameters. Material and methods: This study contains 44 patients with AIM and the blood samples were taken in the time of the admission, 24 hours later and then the fourth or fifth day of hospitalization. We tested the cardiac panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP and GPBB) on the biochip analyser The Evidence InvestigatorTM from Randox (Randox Laboratories Ltd., United Kingdom). Results: Our study confirms the close relationship between FABP and GPBB to AIM and we can consider these markers as early markers in the diagnosis of AIM. FABP has, as the standard markers CKMB or TnI, the prognostic value too (the higher values are associated with the systolic dysfunction). This study employs a new strategy of the biochip analyser in the diagnosis of AIM (in the same time we have the concentrations of more parameters and complex information about AIM). Conclusion: This method presents new interesting multianalytes approach to the diagnosis of the AIM. But this method requires a lot of further studies to verify this technology., Horáková L., Pudil R., Vašatová M., Tichý M., and Literatura